Aerie Pharmaceuticals, Inc. (AERI)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
Pre-market:
| Previous close | 7.23 |
| Open | 7.05 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 3100 |
| Day's range | 7.09 - 7.49 |
| 52-week range | 6.67 - 21.30 |
| Volume | |
| Avg. volume | 1,136,487 |
| Market cap | 336.712M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.61 |
| Earnings date | 23 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.57 |
- Business Wire
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., December 22, 2021--Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
- Business Wire
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
DURHAM, N.C., December 16, 2021--Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
- Business Wire
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
DURHAM, N.C., December 07, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, "Aerie") announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Rocklatan®/Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countr
© 2022 Yahoo. All rights reserved.
